<DOC>
	<DOCNO>NCT00062647</DOCNO>
	<brief_summary>The purpose study determine whether telavancin ( TD-6424 , ARBELIC ) safety administer patient bloodstream infection whether telavancin effective treating infection .</brief_summary>
	<brief_title>Telavancin Treatment Uncomplicated Staphylococcus Aureus Bacteremia</brief_title>
	<detailed_description />
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Gram-Positive Bacterial Infections</mesh_term>
	<mesh_term>Oxacillin</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Telavancin</mesh_term>
	<mesh_term>Nafcillin</mesh_term>
	<mesh_term>Cloxacillin</mesh_term>
	<criteria>Inclusion Criteria Documented S. aureus bacteremia Exclusion Criteria Patients receive would receive 72 hour potentially effective systemic antistaphylococcal therapy within 7 day prior randomization . The following agent consider potentially effective antistaphylococcal therapy : antistaphylococcal penicillin ( include nafcillin , oxacillin , cloxacillin ) , cephalosporin , fluoroquinolones , glycopeptides ( include vancomycin teicoplanin ) linezolid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>